Analyst Andres Y. Maldonado from H.C. Wainwright maintained a Buy rating on Day One Biopharmaceuticals and keeping the price target at $25.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Andres Y. Maldonado has given his Buy rating due to a combination of factors related to Day One Biopharmaceuticals’ strategic acquisition and promising drug pipeline. The acquisition of Mersana introduces Emi Le, a B7 H4 directed Dolasynthen ADC, which has shown significant early monotherapy activity across various high tumor types, including rare cancers like ACC 1. This drug’s differentiated tolerability profile and lack of severe side effects make it a valuable addition to Day One’s portfolio.
Furthermore, Emi Le’s potential rapid regulatory path in ACC 1, a rare cancer with no approved therapies, enhances Day One’s strategic expansion into underserved cancer markets. The drug has demonstrated impressive response rates, outperforming existing therapies in similar conditions. These factors, combined with Day One’s focus on rare cancers and their established clinical infrastructure, support the Buy rating as the company is well-positioned to accelerate development and leverage its commercial capabilities effectively.
In another report released today, Needham also maintained a Buy rating on the stock with a $16.00 price target.